You Searched For: Bioreactors

Upstream processing for cell therapy Compared to production volumes associated with other biologics (e.g. mAbs: 2000L to 10000L) cell therapy production volumes are more commonly between 1L to 10L. Even the quality parameters are different. Instea...

Upstream processing for cell therapy Compared to production volumes associated with other biologics (e.g. mAbs: 2000L to 10000L) cell therapy production volumes are more commonly between 1L to 10L. Even the quality parameters are different. Instea...

PEIpro Poster Reproducibility & Scalability Excellent lot-to-lot protein yield reproducibility using PEIpro®. Suspension HEK-293 cells were seeded at 1×106 cells/mL in serum-free medium and transfected with PEIpro® following the standard protocol....

Fermentation media & supplements Culture media formulation development is not mutually exclusive of the methods for clone selection or the processes used (bioreactor and cells) to achieve the desired cell density and productivity. Our broad offeri...

Fermentation media & supplements Culture media formulation development is not mutually exclusive of the methods for clone selection or the processes used (bioreactor and cells) to achieve the desired cell density and productivity. Our broad offeri...

1.0 0.9 0.8 0.7 0.6 0.5 rM A b (g /L ) 0.4 0.3 0.2 0.1 0 10 9 8 7 6 5 C el l d en si ty (c el ls /m L) 4 3 2 1 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Time (d) Feed Application note 29188433 AA GE Healthcare Production of recombinant monoclonal antib...

1.0 0.9 0.8 0.7 0.6 0.5 rM A b (g /L ) 0.4 0.3 0.2 0.1 0 10 9 8 7 6 5 C el l d en si ty (c el ls /m L) 4 3 2 1 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Time (d) Feed Application note 29188433 AA GE Healthcare Production of recombinant monoclonal antib...

1.0 0.9 0.8 0.7 0.6 0.5 rM A b (g /L ) 0.4 0.3 0.2 0.1 0 10 9 8 7 6 5 C el l d en si ty (c el ls /m L) 4 3 2 1 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Time (d) Feed Application note 29188433 AA GE Healthcare Production of recombinant monoclonal antib...

1.0 0.9 0.8 0.7 0.6 0.5 rM A b (g /L ) 0.4 0.3 0.2 0.1 0 10 9 8 7 6 5 C el l d en si ty (c el ls /m L) 4 3 2 1 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Time (d) Feed Application note 29188433 AA GE Healthcare Production of recombinant monoclonal antib...

Fermentation media & supplements Culture media formulation development is not mutually exclusive of the methods for clone selection or the processes used (bioreactor and cells) to achieve the desired cell density and productivity. Our broad offeri...

VWR® OmniTop Sample Tubes® An innovative solution from our VWR bioprocessing division Any biopharmaceutical production requires frequent in-process sampling to confirm product integrity and conformance. To achieve this an accurate sample must be t...

VWR® OmniTop Sample Tubes® An innovative solution from our VWR bioprocessing division Any biopharmaceutical production requires frequent in-process sampling to confirm product integrity and conformance. To achieve this an accurate sample must be t...

PCR optimization: The next stage Webinar Tuesday 21st September 2021 15:00 to 16:00 SGT REGISTER Email Alerts Free Registration Chat Area Certificate of attendance Webinar Overview A conventional thermal cycler has long been a commodity product in...

VWR® OmniTop Sample Tubes® An innovative solution from our VWR bioprocessing division Any biopharmaceutical production requires frequent in-process sampling to confirm product integrity and conformance. To achieve this an accurate sample must be t...

1.0 0.9 0.8 0.7 0.6 0.5 rM A b (g /L ) 0.4 0.3 0.2 0.1 0 10 9 8 7 6 5 C el l d en si ty (c el ls /m L) 4 3 2 1 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Time (d) Feed Application note 29188433 AA GE Healthcare Production of recombinant monoclonal antib...